KI study ranked among the top 10 at the European Renal Association Congress
An abstract from Karolinska Institutet has been selected as one of the top ten at the European Renal Association (ERA) Congress 2026 in Glasgow, from among 3,172 submitted entries. The study highlights how even small variations within the normal range of albuminuria is associated with adverse clinical outcomes in patients with chronic kidney disease.
The abstract, entitled Normoalbuminuria and subsequent risks of adverse outcomes in patients with CKD: a nationwide cohort study, will be presented at the annual congress of the European Renal Association in June 2026 by Charikleia Chrysostomou, Senior Consultant Nephrologist at Karolinska University Hospital and PhD student at the Rheumatology Division, Department of Medicine, Solna.
The work was carried out in collaboration with her two co-supervisors, Anne-Laure Faucon, Docent at the Department of Clinical Science, Intervention and Technology and the Department of Medical Epidemiology and Biostatistics and Marie Evans, Professor at the Department of Clinical Science, Intervention and Technology.
Using data from the Swedish Renal Registry, the results show that even albuminuria within the normal range is associated with higher risks of chronic kidney disease progression, cardiovascular events, and death. These findings challenge the traditional interpretation of “normal” albuminuria and suggest important implications for risk identification and improved patient management.